Overall survival and post-spontaneous regression relapse-free survival of patients with lymphoproliferative disorders associated with rheumatoid arthritis: a multi-center retrospective cohort study
To clarify factors affecting 5-year survival rates and relapse rates after spontaneous regression (SR) of lymphoproliferative disorders (LPDs) in patients with rheumatoid arthritis (RA). This retrospective longitudinal study comprised 232 patients with RA diagnosed with LPDs between January 2000 and...
Gespeichert in:
| Veröffentlicht in: | Modern rheumatology 2022-01, Vol.ahead-of-print (ahead-of-print), p.1-16 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 16 |
|---|---|
| container_issue | ahead-of-print |
| container_start_page | 1 |
| container_title | Modern rheumatology |
| container_volume | ahead-of-print |
| creator | Saito, Rintaro Tanaka, Masao Ito, Hiromu Kuramoto, Nobuo Fujii, Takao Saito, Shuntaro Kaneko, Yuko Nakano, Kazuhisa Saito, Kazuyoshi Takada, Hideto Sugimoto, Naoki Sasaki, Sho Harigai, Masayoshi Suzuki, Yasuo |
| description | To clarify factors affecting 5-year survival rates and relapse rates after spontaneous regression (SR) of lymphoproliferative disorders (LPDs) in patients with rheumatoid arthritis (RA).
This retrospective longitudinal study comprised 232 patients with RA diagnosed with LPDs between January 2000 and March 2017 at eight hospitals in Japan. The Kaplan-Meier method was used to analyze survival and the Cox proportional hazard model was applied to identify predictive factors.
Among all patients, 1-, 2- and 5-year overall survival rates were 89.5%, 86.1%, and 78.2%, respectively. Multivariable analysis revealed four 5-year survival risk factors assessed at diagnosis: age above 70 years (p = .002), deep lymphadenopathy and/or more than one extranodal lesion (p = .008), Eastern Cooperative Oncology Group/Zubrod performance status of 2-4 (p = .004), and classic Hodgkin lymphoma (CHL) histology (p = .047). Among 143 patients who achieved SR, 2- and 5-year relapse rates were 14.2% and 24.9%, respectively. CHL histology (p = .003) and serum soluble interleukin-2 receptor levels exceeding 2000 IU/L (p = .014) were associated with post-SR relapse-free survival. Blood lymphocyte counts were significantly lower at relapse than at 3-6 months prior (p |
| doi_str_mv | 10.1080/14397595.2020.1866837 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_14397595_2020_1866837</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>33336615</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-43b0ab003a5c528d6411da37ba968ee3db33e88a86c1f66d62fd220ed9d1ad2f3</originalsourceid><addsrcrecordid>eNp9kc1u1DAQxyMEol88AsgvkNaON96EE6iCFqlSL_QcTeIxMXLiaMbZah-Q98LLduGGLx6N_h-Wf0XxXslrJRt5oza63dZtfV3JKq8aYxq9fVWcH_bl1sj29WnOorPigvmnlLpum_ZtcabzMUbV58Wvxx0ShCB4pZ3fQRAwW7FETiUvcU4wY1xZEP4gZPZxzmOAhbF0hPjPFZ1YIHmcE4tnn0YR9tMyxoVi8C43JL9DYT1HskgsgDkOHhLao5pGXCdI0VsBlEbyyfNHAWJaQ_LlkGORcnOiyAsOf8KGOEZKgtNq91fFGweB8d3LfVk8ff3y_fa-fHi8-3b7-aEcdCtTudG9hD5_A9RDXTXWbJSyoLc9tKZB1LbXGpsGGjMoZ4w1lbNVJdG2VoGtnL4s6mPukB_ChK5byE9A-07J7oClO2HpDli6FyzZ9-HoW9Z-QvvXdeKQBZ-OAj-7SBM8Rwq2S7APkRzBPHju9P87fgOcuKWa</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Overall survival and post-spontaneous regression relapse-free survival of patients with lymphoproliferative disorders associated with rheumatoid arthritis: a multi-center retrospective cohort study</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Saito, Rintaro ; Tanaka, Masao ; Ito, Hiromu ; Kuramoto, Nobuo ; Fujii, Takao ; Saito, Shuntaro ; Kaneko, Yuko ; Nakano, Kazuhisa ; Saito, Kazuyoshi ; Takada, Hideto ; Sugimoto, Naoki ; Sasaki, Sho ; Harigai, Masayoshi ; Suzuki, Yasuo</creator><creatorcontrib>Saito, Rintaro ; Tanaka, Masao ; Ito, Hiromu ; Kuramoto, Nobuo ; Fujii, Takao ; Saito, Shuntaro ; Kaneko, Yuko ; Nakano, Kazuhisa ; Saito, Kazuyoshi ; Takada, Hideto ; Sugimoto, Naoki ; Sasaki, Sho ; Harigai, Masayoshi ; Suzuki, Yasuo</creatorcontrib><description>To clarify factors affecting 5-year survival rates and relapse rates after spontaneous regression (SR) of lymphoproliferative disorders (LPDs) in patients with rheumatoid arthritis (RA).
This retrospective longitudinal study comprised 232 patients with RA diagnosed with LPDs between January 2000 and March 2017 at eight hospitals in Japan. The Kaplan-Meier method was used to analyze survival and the Cox proportional hazard model was applied to identify predictive factors.
Among all patients, 1-, 2- and 5-year overall survival rates were 89.5%, 86.1%, and 78.2%, respectively. Multivariable analysis revealed four 5-year survival risk factors assessed at diagnosis: age above 70 years (p = .002), deep lymphadenopathy and/or more than one extranodal lesion (p = .008), Eastern Cooperative Oncology Group/Zubrod performance status of 2-4 (p = .004), and classic Hodgkin lymphoma (CHL) histology (p = .047). Among 143 patients who achieved SR, 2- and 5-year relapse rates were 14.2% and 24.9%, respectively. CHL histology (p = .003) and serum soluble interleukin-2 receptor levels exceeding 2000 IU/L (p = .014) were associated with post-SR relapse-free survival. Blood lymphocyte counts were significantly lower at relapse than at 3-6 months prior (p < .001).
Assessment of the above risk factors and routine inspection of blood lymphocyte counts could aid in the care management of LPDs in RA.</description><identifier>ISSN: 1439-7595</identifier><identifier>EISSN: 1439-7609</identifier><identifier>DOI: 10.1080/14397595.2020.1866837</identifier><identifier>PMID: 33336615</identifier><language>eng</language><publisher>England: Taylor & Francis</publisher><subject>Aged ; Arthritis, Rheumatoid ; Hodgkin Disease ; Humans ; iatrogenic immunosuppression ; Longitudinal Studies ; Lymphoproliferative disorders ; Lymphoproliferative Disorders - diagnosis ; Methotrexate - adverse effects ; Neoplasm Recurrence, Local - chemically induced ; Neoplasm Recurrence, Local - complications ; relapse rate ; Retrospective Studies ; rheumatoid arthritis ; survival rate</subject><ispartof>Modern rheumatology, 2022-01, Vol.ahead-of-print (ahead-of-print), p.1-16</ispartof><rights>2021 Japan College of Rheumatology 2021</rights><rights>2021 Japan College of Rheumatology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-43b0ab003a5c528d6411da37ba968ee3db33e88a86c1f66d62fd220ed9d1ad2f3</citedby><cites>FETCH-LOGICAL-c390t-43b0ab003a5c528d6411da37ba968ee3db33e88a86c1f66d62fd220ed9d1ad2f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33336615$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Saito, Rintaro</creatorcontrib><creatorcontrib>Tanaka, Masao</creatorcontrib><creatorcontrib>Ito, Hiromu</creatorcontrib><creatorcontrib>Kuramoto, Nobuo</creatorcontrib><creatorcontrib>Fujii, Takao</creatorcontrib><creatorcontrib>Saito, Shuntaro</creatorcontrib><creatorcontrib>Kaneko, Yuko</creatorcontrib><creatorcontrib>Nakano, Kazuhisa</creatorcontrib><creatorcontrib>Saito, Kazuyoshi</creatorcontrib><creatorcontrib>Takada, Hideto</creatorcontrib><creatorcontrib>Sugimoto, Naoki</creatorcontrib><creatorcontrib>Sasaki, Sho</creatorcontrib><creatorcontrib>Harigai, Masayoshi</creatorcontrib><creatorcontrib>Suzuki, Yasuo</creatorcontrib><title>Overall survival and post-spontaneous regression relapse-free survival of patients with lymphoproliferative disorders associated with rheumatoid arthritis: a multi-center retrospective cohort study</title><title>Modern rheumatology</title><addtitle>Mod Rheumatol</addtitle><description>To clarify factors affecting 5-year survival rates and relapse rates after spontaneous regression (SR) of lymphoproliferative disorders (LPDs) in patients with rheumatoid arthritis (RA).
This retrospective longitudinal study comprised 232 patients with RA diagnosed with LPDs between January 2000 and March 2017 at eight hospitals in Japan. The Kaplan-Meier method was used to analyze survival and the Cox proportional hazard model was applied to identify predictive factors.
Among all patients, 1-, 2- and 5-year overall survival rates were 89.5%, 86.1%, and 78.2%, respectively. Multivariable analysis revealed four 5-year survival risk factors assessed at diagnosis: age above 70 years (p = .002), deep lymphadenopathy and/or more than one extranodal lesion (p = .008), Eastern Cooperative Oncology Group/Zubrod performance status of 2-4 (p = .004), and classic Hodgkin lymphoma (CHL) histology (p = .047). Among 143 patients who achieved SR, 2- and 5-year relapse rates were 14.2% and 24.9%, respectively. CHL histology (p = .003) and serum soluble interleukin-2 receptor levels exceeding 2000 IU/L (p = .014) were associated with post-SR relapse-free survival. Blood lymphocyte counts were significantly lower at relapse than at 3-6 months prior (p < .001).
Assessment of the above risk factors and routine inspection of blood lymphocyte counts could aid in the care management of LPDs in RA.</description><subject>Aged</subject><subject>Arthritis, Rheumatoid</subject><subject>Hodgkin Disease</subject><subject>Humans</subject><subject>iatrogenic immunosuppression</subject><subject>Longitudinal Studies</subject><subject>Lymphoproliferative disorders</subject><subject>Lymphoproliferative Disorders - diagnosis</subject><subject>Methotrexate - adverse effects</subject><subject>Neoplasm Recurrence, Local - chemically induced</subject><subject>Neoplasm Recurrence, Local - complications</subject><subject>relapse rate</subject><subject>Retrospective Studies</subject><subject>rheumatoid arthritis</subject><subject>survival rate</subject><issn>1439-7595</issn><issn>1439-7609</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1u1DAQxyMEol88AsgvkNaON96EE6iCFqlSL_QcTeIxMXLiaMbZah-Q98LLduGGLx6N_h-Wf0XxXslrJRt5oza63dZtfV3JKq8aYxq9fVWcH_bl1sj29WnOorPigvmnlLpum_ZtcabzMUbV58Wvxx0ShCB4pZ3fQRAwW7FETiUvcU4wY1xZEP4gZPZxzmOAhbF0hPjPFZ1YIHmcE4tnn0YR9tMyxoVi8C43JL9DYT1HskgsgDkOHhLao5pGXCdI0VsBlEbyyfNHAWJaQ_LlkGORcnOiyAsOf8KGOEZKgtNq91fFGweB8d3LfVk8ff3y_fa-fHi8-3b7-aEcdCtTudG9hD5_A9RDXTXWbJSyoLc9tKZB1LbXGpsGGjMoZ4w1lbNVJdG2VoGtnL4s6mPukB_ChK5byE9A-07J7oClO2HpDli6FyzZ9-HoW9Z-QvvXdeKQBZ-OAj-7SBM8Rwq2S7APkRzBPHju9P87fgOcuKWa</recordid><startdate>20220105</startdate><enddate>20220105</enddate><creator>Saito, Rintaro</creator><creator>Tanaka, Masao</creator><creator>Ito, Hiromu</creator><creator>Kuramoto, Nobuo</creator><creator>Fujii, Takao</creator><creator>Saito, Shuntaro</creator><creator>Kaneko, Yuko</creator><creator>Nakano, Kazuhisa</creator><creator>Saito, Kazuyoshi</creator><creator>Takada, Hideto</creator><creator>Sugimoto, Naoki</creator><creator>Sasaki, Sho</creator><creator>Harigai, Masayoshi</creator><creator>Suzuki, Yasuo</creator><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20220105</creationdate><title>Overall survival and post-spontaneous regression relapse-free survival of patients with lymphoproliferative disorders associated with rheumatoid arthritis: a multi-center retrospective cohort study</title><author>Saito, Rintaro ; Tanaka, Masao ; Ito, Hiromu ; Kuramoto, Nobuo ; Fujii, Takao ; Saito, Shuntaro ; Kaneko, Yuko ; Nakano, Kazuhisa ; Saito, Kazuyoshi ; Takada, Hideto ; Sugimoto, Naoki ; Sasaki, Sho ; Harigai, Masayoshi ; Suzuki, Yasuo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-43b0ab003a5c528d6411da37ba968ee3db33e88a86c1f66d62fd220ed9d1ad2f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Aged</topic><topic>Arthritis, Rheumatoid</topic><topic>Hodgkin Disease</topic><topic>Humans</topic><topic>iatrogenic immunosuppression</topic><topic>Longitudinal Studies</topic><topic>Lymphoproliferative disorders</topic><topic>Lymphoproliferative Disorders - diagnosis</topic><topic>Methotrexate - adverse effects</topic><topic>Neoplasm Recurrence, Local - chemically induced</topic><topic>Neoplasm Recurrence, Local - complications</topic><topic>relapse rate</topic><topic>Retrospective Studies</topic><topic>rheumatoid arthritis</topic><topic>survival rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Saito, Rintaro</creatorcontrib><creatorcontrib>Tanaka, Masao</creatorcontrib><creatorcontrib>Ito, Hiromu</creatorcontrib><creatorcontrib>Kuramoto, Nobuo</creatorcontrib><creatorcontrib>Fujii, Takao</creatorcontrib><creatorcontrib>Saito, Shuntaro</creatorcontrib><creatorcontrib>Kaneko, Yuko</creatorcontrib><creatorcontrib>Nakano, Kazuhisa</creatorcontrib><creatorcontrib>Saito, Kazuyoshi</creatorcontrib><creatorcontrib>Takada, Hideto</creatorcontrib><creatorcontrib>Sugimoto, Naoki</creatorcontrib><creatorcontrib>Sasaki, Sho</creatorcontrib><creatorcontrib>Harigai, Masayoshi</creatorcontrib><creatorcontrib>Suzuki, Yasuo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Modern rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Saito, Rintaro</au><au>Tanaka, Masao</au><au>Ito, Hiromu</au><au>Kuramoto, Nobuo</au><au>Fujii, Takao</au><au>Saito, Shuntaro</au><au>Kaneko, Yuko</au><au>Nakano, Kazuhisa</au><au>Saito, Kazuyoshi</au><au>Takada, Hideto</au><au>Sugimoto, Naoki</au><au>Sasaki, Sho</au><au>Harigai, Masayoshi</au><au>Suzuki, Yasuo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Overall survival and post-spontaneous regression relapse-free survival of patients with lymphoproliferative disorders associated with rheumatoid arthritis: a multi-center retrospective cohort study</atitle><jtitle>Modern rheumatology</jtitle><addtitle>Mod Rheumatol</addtitle><date>2022-01-05</date><risdate>2022</risdate><volume>ahead-of-print</volume><issue>ahead-of-print</issue><spage>1</spage><epage>16</epage><pages>1-16</pages><issn>1439-7595</issn><eissn>1439-7609</eissn><abstract>To clarify factors affecting 5-year survival rates and relapse rates after spontaneous regression (SR) of lymphoproliferative disorders (LPDs) in patients with rheumatoid arthritis (RA).
This retrospective longitudinal study comprised 232 patients with RA diagnosed with LPDs between January 2000 and March 2017 at eight hospitals in Japan. The Kaplan-Meier method was used to analyze survival and the Cox proportional hazard model was applied to identify predictive factors.
Among all patients, 1-, 2- and 5-year overall survival rates were 89.5%, 86.1%, and 78.2%, respectively. Multivariable analysis revealed four 5-year survival risk factors assessed at diagnosis: age above 70 years (p = .002), deep lymphadenopathy and/or more than one extranodal lesion (p = .008), Eastern Cooperative Oncology Group/Zubrod performance status of 2-4 (p = .004), and classic Hodgkin lymphoma (CHL) histology (p = .047). Among 143 patients who achieved SR, 2- and 5-year relapse rates were 14.2% and 24.9%, respectively. CHL histology (p = .003) and serum soluble interleukin-2 receptor levels exceeding 2000 IU/L (p = .014) were associated with post-SR relapse-free survival. Blood lymphocyte counts were significantly lower at relapse than at 3-6 months prior (p < .001).
Assessment of the above risk factors and routine inspection of blood lymphocyte counts could aid in the care management of LPDs in RA.</abstract><cop>England</cop><pub>Taylor & Francis</pub><pmid>33336615</pmid><doi>10.1080/14397595.2020.1866837</doi><tpages>16</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1439-7595 |
| ispartof | Modern rheumatology, 2022-01, Vol.ahead-of-print (ahead-of-print), p.1-16 |
| issn | 1439-7595 1439-7609 |
| language | eng |
| recordid | cdi_crossref_primary_10_1080_14397595_2020_1866837 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current) |
| subjects | Aged Arthritis, Rheumatoid Hodgkin Disease Humans iatrogenic immunosuppression Longitudinal Studies Lymphoproliferative disorders Lymphoproliferative Disorders - diagnosis Methotrexate - adverse effects Neoplasm Recurrence, Local - chemically induced Neoplasm Recurrence, Local - complications relapse rate Retrospective Studies rheumatoid arthritis survival rate |
| title | Overall survival and post-spontaneous regression relapse-free survival of patients with lymphoproliferative disorders associated with rheumatoid arthritis: a multi-center retrospective cohort study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T21%3A26%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Overall%20survival%20and%20post-spontaneous%20regression%20relapse-free%20survival%20of%20patients%20with%20lymphoproliferative%20disorders%20associated%20with%20rheumatoid%20arthritis:%20a%20multi-center%20retrospective%20cohort%20study&rft.jtitle=Modern%20rheumatology&rft.au=Saito,%20Rintaro&rft.date=2022-01-05&rft.volume=ahead-of-print&rft.issue=ahead-of-print&rft.spage=1&rft.epage=16&rft.pages=1-16&rft.issn=1439-7595&rft.eissn=1439-7609&rft_id=info:doi/10.1080/14397595.2020.1866837&rft_dat=%3Cpubmed_cross%3E33336615%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/33336615&rfr_iscdi=true |